This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Compound Screening Remove Pharma Companies Related Topics
In-Vivo Gene Editing Genomics Genome Clinical Trials Licensing Gene Therapy FDA Approval Clinical Development Trials More Related Topics >
article thumbnail

Taking a new approach to tackle neurodegenerative diseases

Drug Discovery World

OCTOBER 4, 2022

New York-based Oligomerix is an emerging clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterised by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD) to Alzheimer’s disease (AD).

Development 52
Development In-Vivo Compound Screening Clinical Development 52
article thumbnail

What to expect from drug discovery and development in 2023

Drug Discovery World

JANUARY 26, 2023

As such, 2022 saw a marked fall in ROI for global pharmaceutical companies and their research and development activities. According to research from Deloitte 1 , the average ROI in R&D for global pharma companies fell to just 1.2% in 2022, a steep decline compared to the record 6.8% the industry experienced in 2021.

Development 98
Development Drugs Clinical Trials Clinical Trials 98
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 32,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024